Is INVO BioScience, Inc. overvalued or undervalued?

As of 15 May 2023, the valuation grade for INVO BioScience, Inc. has moved from does not qualify to risky, indicating a significant shift in its risk profile. The company appears to be overvalued given its financial metrics, with a price to book value of just 0.13 and an EV to sales ratio of 1.04, which suggests that the market is pricing the company higher than its fundamental value. Additionally, the ROCE stands at a troubling -69.23% and ROE at -139.69%, highlighting severe inefficiencies in generating returns.
In comparison to its peers, such as Nexalin Technology, Inc. with an EV to EBITDA of -2.0124 and Tivic Health Systems, Inc. with an EV to EBITDA of -0.5580, INVO BioScience's ratios indicate it is not performing favorably within its industry. The negative EV to EBIT of -0.75 further underscores its financial struggles. Given these indicators, INVO BioScience, Inc. is assessed as overvalued in the current market context.